The Cardio-Protectors

**TENORMIN** for moderate hypertension
**TENORMIN LS** for mild and older hypertensives

'Tenormin' and 'Tenormin' LS Prescribing Notes

**PRESENTATION:** 'Tenormin' tablets containing atenolol 100mg are round, bi-convex, orange and film-coated. ‘Tenormin’ LS tablets containing atenolol 50mg are round, bi-convex, orange and film-coated.

**USES:** Management of hypertension.

**DOSAGE:** 'Tenormin' 100mg orally once a day and 'Tenormin' LS orally once a day; some patients may respond adequately to 'Tenormin' low strength.

**CONTRAINDICATIONS:** Heart Block.

**PRECAUTIONS:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia, pregnancy. Caution in patients with chronic obstructive airways disease. 'Tenormin' modifies the tachycardia of hypoglycaemia. Co-administration of Verapamil or Class I antiarrhythmic agents. Withdrawal of clonidine. Withdrawal of beta-blocking drugs should be gradual in patients with ischaemic heart disease.

**SIDE EFFECTS:** Coldness of extremities, bradycardia and muscular fatigue may occur. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta-blockers – consider discontinuance if they occur.

**PACK SIZE AND BASIC NHS COST:** 'Tenormin' 28's £6.98; 'Tenormin' LS 28's £4.88.

**PRODUCT LICENCE NUMBER:** 'Tenormin' 29/122; 'Tenormin' LS 29/86.

'Tenormin,' 'Tenormin' LS are trademarks.

[Full prescribing information is available on request to the Company: Stuart Pharmaceuticals Limited, Carr House, Carrs Road, Cheadle, Cheshire, SK8 2EG.]
Hypertension?

Adalat Retard
(nifedipine)

relieves the pressure

Prescribing Information. Presentation:
Pink-grey coated tablets each containing 20mg nifedipine. Indications: For the treatment of hypertension. Dosage and Administration: The recommended dose for Adalat Retard is one 20mg tablet twice daily and if necessary a further tablet may be taken according to the patient’s response. Treatment may be continued indefinitely. Contra-Indications: Must not be given to women capable of child bearing. Warnings and Precautions: Adalat Retard is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal, any such withdrawal should be by gradual reduction of the dose of beta-blocker, preferably over 8-10 days. Adalat Retard may be used in combination with beta-blocking drugs and other anti-hypertensive agents, but the possibility of an additive effect resulting in postural hypotension should be borne in mind. Adalat Retard will not prevent possible rebound effects after cessation of anti-hypertensive therapy. Adalat Retard should be used with caution in patients whose cardiac reserve is poor. Ischaemic pain has been reported in some patients, commonly within 30 minutes of the introduction of nifedipine therapy. Patients experiencing this effect should discontinue nifedipine. The use of nifedipine in diabetic patients may require adjustment of their control. There is no known drug incompatibility. Side Effects: Adalat Retard is well tolerated. Minor side-effects, usually associated with vasodilatation, are mainly headache, flushing and lethargy. These are transient and invariably disappear with continued treatment. Overdosage – standard measures such as atropine and noradrenaline may be used for resultant bradycardia and hypotension. Intravenous calcium gluconate may be of benefit. Pack Quantities: Adalat Retard tablets are available in foil strips of 10 in packs of 100. Daily Treatment Cost: 35p. Product Licence Number: Adalat Retard UK. PL0010/0078.

Further information is available from:
Bayer UK Limited, Pharmaceutical Division, Bayer House, Strawberry Hill, Newbury, Berks, RG13 1JA.
Telephone: (0635) 39000. Registered trademark of Bayer, Germany.